2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004)
复制标题
DOI：
10.1093/annonc/mdi961
复制
发表时间：
2005-10-01
影响因子：
50.5
通讯作者：
Wagner, U
中科院分区：
文献类型：
--
作者：
du Bois, A;Quinn, M;Wagner, U
妇科癌症国际小组（GCIG）及其成员组织：1 AGO-OVAR（德国），2 ANZGOG（澳大利亚-新西兰）、4 EORTC（欧洲）、6 GEICO（西班牙）、9 GINECO（法国）、3GOG（美国）、8 JGOG（日本）、10 MRC/NCRI（英国）、7 NCIC-CTG（加拿大）、15 NCI-US（美国）、5 NSGO（Scandinavia），12RTOG（USA），11SGCTG（苏格兰），以及14 IGCS和13两个先前国际OCCC的组织团队的代表-基于共识的声明是重要的，以便定义和更新护理标准，并不仅作为全世界社区的指导方针，也为今后的研究提供了合理的依据。前两次成功的国际卵巢癌共识会议（OCCC）分别于1993年在丹麦埃尔西诺[1]和5年后在荷兰的卑尔根安泽[2]举行，在那里就许多问题达成共识，包括生物学和预后因素，目前最好的治疗方法，手术和医学，以及晚期疾病未来研究的方向。从那时起，国际合作变得更加广泛，组间研究现在普遍作为进行大型随机临床试验的机制。妇科癌症国际组织（GCIG）目前由13个国家和国际合作成员团体和政府组织组成。2002年，GCIG大会投票决定计划第三届国际OCCC，以更正式的程序在研究组之间就临床试验的方法和标准要求达成共识，以指导其他国家和国际妇科肿瘤研究组的工作。预计OCCC声明还将指导一般医学界，并支持制药业制定适当的战略，以改善患有这种疾病的妇女的结果。
Gynecological Cancer Intergroup (GCIG) and its member organizations: 1AGO-OVAR (Germany), 2ANZGOG (Australia–New Zealand), 4EORTC (Europe), 6GEICO (Spain), 9GINECO (France), 3GOG (USA), 8JGOG (Japan), 10MRC/NCRI (UK), 7NCIC-CTG (Canada), 15NCI-US (USA), 5NSGO (Scandinavia), 12RTOG (USA), 11SGCTG (Scotland), and with representation of 14IGCS and 13the organizational team of the two prior International OCCCInternational evidence-based consensus statements are important in order to define and update standards of care and to serve not only as guidelines to communities worldwide, but also to provide a rational basis for future research. Two previous successful international ovarian cancer consensus conferences (OCCC) were held in Elsinore, Denmark in 1993 [1] and 5 years later in Bergen aan Zee, The Netherlands [2], where consensus statements were developed on a number of issues including biological and prognostic factors, best current therapy, both surgical and medical, and directions for future research in advanced disease. Since then, international cooperation has become more extensive and intergroup studies are now common as a mechanism to conduct large randomized clinical trials. The Gynecological Cancer Intergroup (GCIG) now constitutes 13 national and international cooperative member groups and governmental organizations [3]. In 2002, the GCIG’s general assembly voted to plan the 3rd International OCCC with a more formal process to achieve consensus among the study groups on methodology and standard requirements for clinical trials so as to guide other national and international study groups working in gynecologic oncology. It was anticipated that the OCCC statements would also guide the general medical community and support the pharmaceutical industry in developing appropriate strategies to improve the outcome of women with this disease.